Table 1.
Characteristics and results of 76 children who completed the study before and after treatment with vitamin E or placebo
| Vitamin E | Placebo | |
| Total | 56 | 20 |
| Sex (%) | ||
| Female | 22 (39.3) | 8 (40) |
| Male | 34 (60.7) | 12 (60) |
| Age (yr) | 10.4 | 11.8 |
| Alanine transaminase level (%) | ||
| Normal | 33 (58.9) | 13 (65) |
| Elevated | 23 (41.1) | 7 (35) |
| More than double above normal level | 8 | 2 |
| HBV-DNA (%) | ||
| < 1000 pg/mL | 22 (39.3) | 7 (35) |
| > 1000 pg/mL | 35 (60.7) | 13 (65) |
| Route of transmission (%) | ||
| Parenteral | 1 (1.8) | 1 (5) |
| Vertical | 34 (60.7) | 10 (50) |
| Unknown | 21 (37.5) | 9 (45) |
| Interferon alpha pre-treatment (%)1 | 11 (19.6) | 4 (20) |
| Lamivudine pre-treatment (%)1 | 5 (8.9) | 3 (15) |
| HBeAg seroconversion (%)2 | 16 (28.6) | 2 (10) |
1
Four patients were treated first with interferon alpha and re-treated with Lamivudine;
2
12 mo follow-up evaluation after end of treatment.